From an innovation standpoint, this study is the first to systematically validate the role of rhein in modulating hepatic lipid metabolism through the AMPK/ACC/SREBP1 pathway in the context of NAFLD, thereby providing a potential new candidate for NAFLD therapy. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.